PMID- 26286450 OWN - NLM STAT- MEDLINE DCOM- 20160309 LR - 20181202 IS - 1471-2334 (Electronic) IS - 1471-2334 (Linking) VI - 15 DP - 2015 Aug 19 TI - Personality disorders do not affect treatment outcomes for chronic HCV infection in Spanish prisoners: the Perseo study. PG - 355 LID - 10.1186/s12879-015-1102-x [doi] LID - 355 AB - BACKGROUND: The link between infection with hepatitis C virus (HCV) and personality disorders (PD) has not been investigated in detail. The aim of this study was to compare the effectiveness of HCV treatment in prisoners with and without PD. METHODS: We performed a prospective multicentre study in inmates from 25 Spanish prisons who had been treated with pegylated interferon alfa-2a plus ribavirin in 2011. PD diagnosis was based on the Personality Diagnostic Questionnaire-4+. We calculated adjusted Odds Ratios (AOR) and 95 % confidence intervals (95 % CI) using logistic regression. RESULTS: The sample included 236 patients (mean age: 40.3 years, 92.8 % male, 79.2 % intravenous drug users, and 26.3 % HIV-coinfected). The prevalence of PD was 72.5 %. 32.2 % of patients discontinued treatment; this percentage was higher in patients with HCV genotypes 1/4 (AOR = 3.55; CI:1.76-7.18) and those without PD (AOR = 2.51; 1.23-5.11). Treatment discontinuation was mainly for penitentiary reasons (40.3 %): release or transfer between prisons. The rate of sustained viral response (SVR) was 52.1 % by ITT and 76.9 % by observed treatment (OT). SVR was higher among patients with genotype 2 or 3, and those with low baseline HCV-RNA. We did not observe any differences between individuals with and without PD in term of SVR, HCV genotype or HIV infection. CONCLUSIONS: Our results support the safety and clinical effectiveness of the treatment of chronic HCV infection in correctional facilities, both in prisoners with PD and those without. Our data support non-discrimination between patients with and without PD when offering treatment for HCV infection to prison inmates. TRIAL REGISTRATION: Trial registration number (TRN) NCT01900886 . Date of registration: July 8, 2013. FAU - Marco, Andres AU - Marco A AD - Barcelona Men's Penitentiary Health Services, Barcelona, Spain. amarco@aspb.cat. AD - CIBER Epidemiology and Public Health (CIBERESP), Barcelona, Spain. amarco@aspb.cat. FAU - Anton, Jose J AU - Anton JJ AD - Albolote Penitentiary Health Services, Granada, Spain. quinoab@gmail.com. FAU - Trujols, Joan AU - Trujols J AD - Department of Psychiatry, Hospital de la Santa Creu i Sant Pau, Sant Pau Biomedical Research Institute (IIB Sant Pau), CIBER Salud Mental (CIBERSAM), Barcelona, Spain. jtrujols@santpau.cat. FAU - Saiz de la Hoya, Pablo AU - Saiz de la Hoya P AD - Fontcalent Penitentiary Health Services, Alicante, Spain. pabloshz@coma.es. FAU - de Juan, Jose AU - de Juan J AD - Cordoba Penitentiary Health Services, Cordoba, Spain. vivaperejil1@gmail.com. FAU - Faraco, Inmaculada AU - Faraco I AD - Sevilla Penitentiary Health Services, Sevilla, Spain. ifaraco60@gmail.com. FAU - Cayla, Joan A AU - Cayla JA AD - CIBER Epidemiology and Public Health (CIBERESP), Barcelona, Spain. jcayla@aspb.cat. AD - Epidemiology Service, Barcelona Public Health Agency, Plaza Lesseps 1, 08023, Barcelona, Spain. jcayla@aspb.cat. CN - Perseo Group LA - eng SI - ClinicalTrials.gov/NCT01900886 PT - Clinical Study PT - Journal Article PT - Multicenter Study DEP - 20150819 PL - England TA - BMC Infect Dis JT - BMC infectious diseases JID - 100968551 RN - 0 (Antiviral Agents) RN - 0 (Interferon-alpha) RN - 0 (Recombinant Proteins) RN - 3WJQ0SDW1A (Polyethylene Glycols) RN - 49717AWG6K (Ribavirin) RN - Q46947FE7K (peginterferon alfa-2a) SB - IM MH - Adult MH - Antiviral Agents/*therapeutic use MH - Coinfection/drug therapy MH - Drug Therapy, Combination MH - Female MH - Genotype MH - HIV Infections/complications/drug therapy MH - Hepacivirus/genetics MH - Hepatitis C/drug therapy MH - Hepatitis C, Chronic/complications/*drug therapy/psychology MH - Humans MH - Interferon-alpha/*therapeutic use MH - Logistic Models MH - Male MH - Middle Aged MH - Odds Ratio MH - Personality Disorders/complications/*psychology MH - Polyethylene Glycols/*therapeutic use MH - Prisoners/*psychology MH - Prisons MH - Prospective Studies MH - Recombinant Proteins/therapeutic use MH - Ribavirin/*therapeutic use MH - Spain MH - Treatment Outcome MH - Young Adult PMC - PMC4545785 FIR - Alia, C IR - Alia C FIR - Amaya, F IR - Amaya F FIR - Antolin, J M IR - Antolin JM FIR - Borrego, J IR - Borrego J FIR - Campo, E IR - Campo E FIR - da Silva, A IR - da Silva A FIR - Diaz, J R IR - Diaz JR FIR - Domingo, J IR - Domingo J FIR - Gallego, C IR - Gallego C FIR - Garcia-Guerrero, J IR - Garcia-Guerrero J FIR - Herrero, A M IR - Herrero AM FIR - Jimenez-Galan, G IR - Jimenez-Galan G FIR - Laine, J M IR - Laine JM FIR - Leandro, E IR - Leandro E FIR - Lopez, C IR - Lopez C FIR - Muros, R IR - Muros R FIR - Paniagua, F IR - Paniagua F FIR - Perez de los Cobos, J IR - Perez de los Cobos J FIR - Perez-Valenzuela, A IR - Perez-Valenzuela A FIR - Planella, R IR - Planella R FIR - Pozo, E IR - Pozo E FIR - Rebolledo, J R IR - Rebolledo JR FIR - Sanchez-Arrobas, P IR - Sanchez-Arrobas P FIR - Sarriera, C IR - Sarriera C FIR - Sole, C IR - Sole C FIR - Vasallo, L C IR - Vasallo LC FIR - Veiras, M IR - Veiras M FIR - Yllobre, C IR - Yllobre C FIR - Zuniga, J IR - Zuniga J EDAT- 2015/08/20 06:00 MHDA- 2016/03/10 06:00 PMCR- 2015/08/19 CRDT- 2015/08/20 06:00 PHST- 2015/02/10 00:00 [received] PHST- 2015/08/12 00:00 [accepted] PHST- 2015/08/20 06:00 [entrez] PHST- 2015/08/20 06:00 [pubmed] PHST- 2016/03/10 06:00 [medline] PHST- 2015/08/19 00:00 [pmc-release] AID - 10.1186/s12879-015-1102-x [pii] AID - 1102 [pii] AID - 10.1186/s12879-015-1102-x [doi] PST - epublish SO - BMC Infect Dis. 2015 Aug 19;15:355. doi: 10.1186/s12879-015-1102-x.